Evidence map›Paper›PMID 40264918›Full record

ArticleJCO oncology advances2025

SWOG 2308: Randomized Phase III Study of Mosunetuzumab Versus Rituximab for Low-Tumor Burden Follicular Lymphoma.

Nilanjan Ghosh, Shay Bellasea, Hongli Li, Adam J Olszewski, Locke Bryan, Alexey Danilov, Sonali Smith, Michael LeBlanc, Jonathan W Friedberg

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCO oncology advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Nilanjan GhoshAtrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC.ORCID https://orcid.org/0000-0002-3848-6136
Shay BellaseaSWOG Statistics & Data Management Center, Fred Hutchinson Cancer Center, Seattle, WA.
Hongli LiSWOG Statistics & Data Management Center, Fred Hutchinson Cancer Center, Seattle, WA.ORCID https://orcid.org/0009-0009-3063-3670
Adam J OlszewskiBrown University, Providence, RI.ORCID https://orcid.org/0000-0002-6472-6658
Locke BryanGeorgia Cancer Center, Augusta University, Augusta, GA.ORCID https://orcid.org/0000-0002-2244-2569
Alexey DanilovCity of Hope Comprehensive Cancer Center, Duarte, CA.
Sonali SmithUniversity of Chicago, Chicago, IL.
Michael LeBlancSWOG Statistics & Data Management Center, Fred Hutchinson Cancer Center, Seattle, WA.
Jonathan W FriedbergWilmot Cancer Institute, University of Rochester, Rochester, NY.

Funding

SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PRIMO N. LARA · 2014 to 2026
$152.1M
SWOG Statistics & Data Management Center complex - extension supplement for GY06U10CA180819 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Michael L. LeBlanc · 2014 to 2026
$115.2M
Rochester Network Lead Academic Participating SiteUG1CA233230 · NCI · UNIVERSITY OF ROCHESTER · PI Paul M Barr · 2019 to 2026
$6.9M
NCI NIH HHS U10 CA180819NCI NIH HHS U10 CA180888NCI NIH HHS UG1 CA233230
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40264918
PMCPMC12011429

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.